Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Chemoradiotherapy in Stage III NSCLC With EGFR Mutation
NCT02407366Phase 2Unknown
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02407366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407366.